Capital Group Global Growth Equity ETF (CGGO)
- Previous Close
29.39 - Open
29.55 - Bid 29.52 x 1200
- Ask 29.57 x 1400
- Day's Range
29.50 - 29.75 - 52 Week Range
23.44 - 30.72 - Volume
568,520 - Avg. Volume
606,730 - Net Assets 4.5B
- NAV 29.54
- PE Ratio (TTM) 27.40
- Yield 0.93%
- YTD Daily Total Return 15.69%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.47%
The fund invests primarily in common stocks of companies around the world that the investment adviser believes have the potential for growth. It normally invests at least 80% of its assets in equity securities. Under normal market conditions, the fund will invest significantly in issuers domiciled outside the United States (i.e., at least 40% of its net assets, unless market conditions are not deemed favorable by the fund’s investment adviser, in which case the fund would invest at least 30% of its net assets in issuers domiciled outside the United States). It is non-diversified.
Capital Group
Fund Family
Global Large-Stock Growth
Fund Category
4.5B
Net Assets
2022-02-22
Inception Date
Performance Overview: CGGO
View MoreTrailing returns as of 11/1/2024. Category is Global Large-Stock Growth.
People Also Watch
Holdings: CGGO
View MoreTop 10 Holdings (32.84% of Total Assets)
Sector Weightings
Related ETF News
View More
Research Reports: CGGO
View MoreDaily – Vickers Top Buyers & Sellers for 11/01/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Pfizer Earnings: Maintaining Our Valuation as Management Pressed for Evidence of Productivity
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
RatingPrice TargetDepressed Truckload Rates Keeping Hub Group's Intermodal Pricing Off Track
Hub Group ranks among the largest providers of rail intermodal service. Roughly 60% of revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset light truck brokerage operations, along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub is somewhat acquisitive in that it often makes tuck-in acquisitions which expand its brokerage, last-mile, and dedicated offerings.
RatingPrice TargetPort Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
Knight-Swift is the largest truckload carrier in the US, with a diversified transportation offering. Pro forma for the U.S. Xpress deal, about 82% of revenue derives from Knight’s asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload at 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.
RatingPrice Target